These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27720165)

  • 1. Policy interventions related to medicines: Survey of measures taken in European countries during 2010-2015.
    Vogler S; Zimmermann N; de Joncheere K
    Health Policy; 2016 Dec; 120(12):1363-1377. PubMed ID: 27720165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical policies in European countries in response to the global financial crisis.
    Vogler S; Zimmermann N; Leopold C; de Joncheere K
    South Med Rev; 2011 Dec; 4(2):69-79. PubMed ID: 23093885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries.
    Leopold C; Mantel-Teeuwisse AK; Vogler S; Valkova S; de Joncheere K; Leufkens HG; Wagner AK; Ross-Degnan D; Laing R
    Bull World Health Organ; 2014 Sep; 92(9):630-640D. PubMed ID: 25378754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries.
    Vogler S; Österle A; Mayer S
    Int J Equity Health; 2015 Nov; 14():124. PubMed ID: 26541292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Policy in Romania.
    Radu CP; Pana BC; Furtunescu FL
    Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Policy in Greece.
    Yfantopoulos JN; Chantzaras A
    Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Policies and availability of orphan medicines in outpatient care in 24 European countries.
    Sarnola K; Ahonen R; Martikainen JE; Timonen J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of external reference pricing systems in Europe.
    Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
    Vogler S; Schneider P; Zuba M; Busse R; Panteli D
    Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of Medicine Prices in New Zealand and 16 European Countries.
    Vogler S; Kilpatrick K; Babar ZU
    Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of French generic medicines retail market: why the use of generic medicines is limited.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):795-803. PubMed ID: 25095903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab.
    Leopold C; Vogler S; Habl C; Mantel-Teeuwisse AK; Espin J
    Health Policy; 2013 Dec; 113(3):313-22. PubMed ID: 24409503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
    Heo JH; Rascati KL; Lee EK
    Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.
    Rigter H
    Pharmacoeconomics; 1994; 6 Suppl 1():15-21. PubMed ID: 10155581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the financial crisis on human resources for health policies in three southern-Europe countries.
    Correia T; Dussault G; Pontes C
    Health Policy; 2015 Dec; 119(12):1600-5. PubMed ID: 26319095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.
    Vogler S; Habl C; Bogut M; Voncina L
    Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.